NantKwest (NK) and Its Peers Critical Comparison
NantKwest (NASDAQ: NK) is one of 294 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare NantKwest to similar companies based on the strength of its dividends, analyst recommendations, valuation, earnings, profitability, institutional ownership and risk.
Earnings & Valuation
This table compares NantKwest and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|NantKwest Competitors||$473.33 million||$171.77 million||-7.04|
NantKwest’s competitors have higher revenue and earnings than NantKwest. NantKwest is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This is a summary of recent ratings for NantKwest and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
NantKwest currently has a consensus target price of $5.33, indicating a potential upside of 4.17%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 27.71%. Given NantKwest’s competitors stronger consensus rating and higher probable upside, analysts plainly believe NantKwest has less favorable growth aspects than its competitors.
This table compares NantKwest and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
18.8% of NantKwest shares are owned by institutional investors. Comparatively, 51.4% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 70.2% of NantKwest shares are owned by company insiders. Comparatively, 16.3% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
NantKwest has a beta of 3.5, meaning that its stock price is 250% more volatile than the S&P 500. Comparatively, NantKwest’s competitors have a beta of 6.57, meaning that their average stock price is 557% more volatile than the S&P 500.
NantKwest competitors beat NantKwest on 9 of the 12 factors compared.
NantKwest Company Profile
NantKwest, Inc. is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. Its immuno-oncology NK platform has multiple modes to induce cell death against the tumor or infected cell by direct killing by binding to stress ligands expressed by the diseased cell with the release of toxic granules directly into the tumor cell; antibody mediated killing by binding to antibodies administered in combination and enhancing the cancer killing effect of the administered antibody, enabling targeted cell killing through antibody dependent cellular cytotoxicity (ADCC), and target activated killing by binding to known or newly discovered tumor-specific antigens expressed on the surface of tumor cells and inducing cell death by the release of toxic granules directly into the tumor cell and by the release of cytokines and chemokines.
Receive News & Ratings for NantKwest Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantKwest Inc. and related companies with MarketBeat.com's FREE daily email newsletter.